Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management
This article was originally published in RPM Report
Executive Summary
A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.